Skip to main content
Premium Trial:

Request an Annual Quote

Waters Nearly Doubles Q3 Profit, Revenues Increase 10 Percent

NEW YORK (GenomeWeb News) - Waters today reported a 10 percent increase in revenues and nearly doubled net income for the third quarter of 2005.
 
The mass spectrometry, chromatography and software company posted net income of $50.4 million for the quarter ended Sept. 30 –- a 96-percent increase over $25 million last year.
 
Total revenue rose to $300 million from $273 million in the third quarter of 2005.
 
Company chairman, president, and CEO Douglas Berthiaume credited the revenue increase to improved pharmaceutical spending in the US, expanding sales in Asia, efficient operations, and “overall positive acceptance and uptake” of the company's Acquity UPLC system. 
 
R&D spending rose to $19.1 million from $17 million in the prior-year period.
 
As of Sept. 30, Waters had $511.6 million in cash and cash equivalents.

The Scan

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.

Coronary Artery Disease Risk Loci, Candidate Genes Identified in GWAS Meta-Analysis

A GWAS in Nature Genetics of nearly 1.4 million coronary artery disease cases and controls focused in on more than 200 candidate causal genes, including the cell motility-related myosin gene MYO9B.

Multiple Sclerosis Contributors Found in Proteome-Wide Association Study

With a combination of genome-wide association and brain proteome data, researchers in the Annals of Clinical and Translational Neurology tracked down dozens of potential multiple sclerosis risk proteins.

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.